Genomic alterations in TET2 and EZH2 serve as critical drivers of clonal malignant evolution in anti-BCMA CAR-T therapy for multiple myeloma.

作者
Adolfo Aleman,Rudra Prasad Dutta,Oliver Van Oekelen,David T. Melnekoff,Tarek H. Mouhieddine,Leah Grossman,Sidorela Reci,Shilpa Desai,Patrick Manfred Brunner,Alessandro Laganà,Sundar Jagannath,Joshua Brody,Samir Sunil Parekh
出处
期刊:Blood [Elsevier BV]
卷期号:146 (Supplement 1): 3946-3946
标识
DOI:10.1182/blood-2025-3946
摘要

Abstract Background: B cell maturation antigen (BCMA) targeted Chimeric antigen receptor (CAR) T cell therapy has emerged as a transformative treatment for patients with relapsed or refractory multiple myeloma (RRMM), demonstrating deep and durable responses. Nevertheless, emerging reports of secondary hematologic malignancies, particularly of T-cell origin, introduce a new dimension of complexity to the safety profile of these engineered cell therapies. We recently reported a patient with CD4 and CD8 negative PTCL responding to targeted therapy including anti-CCR4 antibody (Aleman et al, NEJM, 2025). This and other sporadic reports of T-cell neoplasms following CAR-T infusion in MM patients necessitate deeper investigation into the pathophysiology, which likely involves a multifactorial interplay between vector integration, clonal hematopoiesis and immune perturbations induced by lymphodepletion or viral infections. Here, we delineate the pathogenesis in our patient with CAR+ peripheral T-cell lymphoma with involvement of the skin, peripheral blood (PB), and bone marrow (BM) emerging in the aftermath of anti-BCMA CAR T cell therapy. Methods We isolated CAR+ peripheral T-cell lymphoma (PTCL) from PB and performed single cell sequencing, RNA sequencing, and functional experiments to characterize the secondary malignancy post anti-BCMA CAR-T therapy. To dissect the genomic drivers that contributed to the secondary malignancy we generated CAR-T cells from healthy donors and from the PTCL patient and knocked down mutational targets. We characterized the functional result of TET2 and EZH2 in single and double knock down mutants byusing BCMA expressing cell lines to elicit an antigen specific response of lab generated CAR-T cells. Results A 51-year-old male presented with a facial lesion and lymphocytosis due to a CD4-/CD8- PTCL involving skin, blood, and bone marrow six months post anti-BCMA CAR-T infusion, Single cell sequencing and bulk RNA sequencing of PTCL tumor revealed the development of new mutations in TET2 and EZH2 which are associated with clonal hematopoiesis of indeterminate potential (CHIP) and T-cell lymphomas. We generated CAR-T cells from a healthy donor and the PTCL patient at the time of apheresis and compared functionality to isolated malignant CAR-T cells from the PB. Antigen specific stimulation with BCMA expressing cell lines revealed loss of function in cytokine production capacity in malignant CAR-T cells not seen in control CAR-T. The cytotoxic capability of malignant tumor CAR-T cells against BCMA expressing cells was decreased by 98% compared to cells generated from PB harvested prior to CART therapy (p<0.01). To discern the contribution of genomic mutations we generated EZH2 and TET2 CAR-T mutants from healthy donor and PB harvested prior to CART therapy from our PTCL patient. EZH2 inhibition in CAR-T cells increased CD69, CD38 and CD127 while reducing FAS expression resisting apoptosis. TET2 knock down in CAR-T cells resulted in increased proliferation and doubled the expression of in CCR4+ compared to control. CCR4+ is a skin homing chemokine which was expressed in all our patient’s malignant CAR-T tumor cells and served as an indicator for treatment with mogamulizumab. EZH2 and TET2 double mutant almost tripled the expression of CCR4 compared to control and caused a loss of CD7 in 73% of cells. Loss of CD7 is hallmark of T cell lymphomas. Knock down of TET2 and EZH2 resulted in a decrease in functional killing. EZH2 knockdown mutant resulted in a 28% reduction of cytotoxicity while TET2 knock down reduced killing by 53% when compared to control CAR-T cells (p<0.05). Double knock down of TET2 and EZH2 further decreased overall cytotoxicity by 67% (p<0.01). Conclusions TET2 and EZH2 mutations result in epigenetic changes such as open chromatin, leaving the genome more vulnerable to additional alterations. TET2 and EZH2-loss of function mutations in CAR-T cells provide advantages in proliferation and regeneration while promoting malignant CAR-T transformation following anti-BCMA CAR-T therapy.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
小兔叽完成签到 ,获得积分10
4秒前
Allen完成签到,获得积分10
5秒前
force完成签到 ,获得积分10
5秒前
asdasdf完成签到,获得积分10
6秒前
chic完成签到 ,获得积分10
6秒前
红颜如梦完成签到 ,获得积分10
6秒前
闪闪慕蕊完成签到 ,获得积分10
7秒前
熙可檬完成签到 ,获得积分10
7秒前
充电宝的应助被ping采纳,获得10
7秒前
wawaeryu完成签到,获得积分10
8秒前
hjj完成签到 ,获得积分10
10秒前
余闻问完成签到,获得积分10
11秒前
11秒前
san完成签到,获得积分10
12秒前
Health完成签到 ,获得积分10
14秒前
2520完成签到 ,获得积分10
15秒前
MJMO完成签到,获得积分10
15秒前
相宜完成签到,获得积分10
16秒前
墨玖辰完成签到,获得积分10
17秒前
高高的哈密瓜完成签到 ,获得积分10
18秒前
阿臭der完成签到 ,获得积分10
18秒前
搬砖的化学男完成签到 ,获得积分10
18秒前
sun完成签到,获得积分10
19秒前
zhouyms完成签到,获得积分10
21秒前
神通广大的MOMO完成签到,获得积分10
22秒前
美满的机器猫完成签到,获得积分10
25秒前
27秒前
Gabi完成签到,获得积分10
27秒前
31秒前
WWW完成签到 ,获得积分10
31秒前
waldoe完成签到,获得积分10
31秒前
32秒前
Laser_eyes完成签到,获得积分10
32秒前
大胆的弼完成签到,获得积分10
32秒前
33秒前
GGG完成签到 ,获得积分10
33秒前
朴素傲松完成签到,获得积分10
33秒前
34秒前
34秒前
35秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8185537
求助须知:如何正确求助?哪些是违规求助? 9574270
关于积分的说明 21834871
捐赠科研通 7783247
什么是DOI,文献DOI怎么找? 3434577
关于科研通互助平台的介绍 2558951
邀请新用户注册赠送积分活动 2481370